Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
138
datasets available to search
ShareScore release 0.7.1
Dataset results
138 results for “viral hepatitis”
Hepatitis B virus deregulates cell cycle to promote viral replication and a premalignant phenotype
GEO Series GSE118295. Homo sapiens. 6 samples. Type: Expression profiling by array.
Liver transcriptome profiles correlates with viral control during hepatitis B virus infection
GEO Series GSE65359. Homo sapiens. 83 samples. Type: Expression profiling by array.
si RNA interference of Hepatitis B viral gene expression
GEO Series GSE3992. Homo sapiens. 12 samples. Type: Expression profiling by array.
A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)
ClinicalTrials.gov study NCT01770223. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B
ClinicalTrials.gov study NCT00710216. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
ClinicalTrials.gov study NCT02308319. IPD Sharing: Not stated. Countries: 0. Publications: 0.
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Phase I Study on Safety and Efficacy of Mesenchymal Stem-Cell (MSC) Therapy in Non-Viral Acute-on-Chronic Liver Failure (ACLF
ClinicalTrials.gov study NCT07131540. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir
ClinicalTrials.gov study NCT03236584. IPD Sharing: NO. Countries: 0. Publications: 0.
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low
ClinicalTrials.gov study NCT00724230. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Characteristic and Survival Outcomes in Hepatocellular Carcinoma Patients: on Top of Viral Hepatitis Versus Combined Viral and Metabolic-Associated Steatotic Liver Disease
ClinicalTrials.gov study NCT06871930. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Case Control Study of Non Viral Hepatitis Relating to Herbal Drug Use in the Emergency Department
ClinicalTrials.gov study NCT00201578. IPD Sharing: Not stated. Countries: 1. Publications: 0.
AMPK activation in response to hepatitis E virus infection inhibited viral replication by attenuating autophagosome and promoting innate immunity
GEO Series GSE262469. Homo sapiens. 15 samples. Type: Expression profiling by high throughput sequencing.
Coordinated analysis of hepatic host responses to Dengue virus infection reveals a role for Hsp90 in viral replication
GEO Series GSE86286. Homo sapiens. 12 samples. Type: Expression profiling by array.
Transcriptional profiling of liver biopsies of precancerous viral hepatitis patients: Validation cohort
GEO Series GSE237331. Homo sapiens. 50 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study "
<p>This record contains raw data related to article “Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study"</p> <p>Abstract</p> <p><strong>Introduction: </strong> There are no strong data regarding the treatment with biologics (especially for the most recent anti-IL-17 and anti-IL-23 drugs) of patients with psoriasis and concomitant viral hepatitis. We assessed the safety of biologic drugs in patients with psoriasis who are seropositive for hepatitis B or C and did not receive antiviral prophylaxis.</p> <p><strong>Methods: </strong> We conducted a retrospective single-center study. The efficacy of biologic treatments was evaluated by assessing the Psoriasis Area and Severity Index (PASI) score during all visits, for a minimum follow-up of 52 weeks. All patients were evaluated by a hepatologist before starting the treatment. They were monitored for reactivation of viral hepatitis.</p> <p><strong>Results: </strong> Twenty patients had positive markers of hepatitis B virus (HBV) or hepatitis C virus (HCV). Seventeen patients had positive markers of HBV infection, and four patients had antibodies for HCV (one patient had serologic evidence of both infections). Anti-IL-23 biologics were the most used in our population, with risankizumab being the most prescribed drug. No patient had evidence of viral reactivation during our study. Study limitations include its retrospective nature and our inclusion of patients with different serological status receiving different biologic drugs.</p> <p><strong>Conclusion: </strong> Biologic therapies (including anti-IL-23 drugs) appear to be safe in patients seropositive for HCV or HBV core antibody who did not receive antiviral prophylaxis.</p>
Effects of Sho-saiko-to, a Herbal Formula, in Reducing Viral Load in Hepatitis C
ClinicalTrials.gov study NCT00633230. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Transcriptional profiling of liver biopsies of precancerous viral hepatitis patients: Training cohort
GEO Series GSE237330. Homo sapiens. 56 samples. Type: Expression profiling by high throughput sequencing.
Transcriptional profiling of liver biopsies of precancerous viral hepatitis patients
GEO Series GSE237332. Homo sapiens. 106 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.